Peter Bach height - How tall is Peter Bach?
Peter Bach was born on 1964, is a Medical researcher. At 56 years old, Peter Bach height not available right now. We will update Peter Bach's height soon as possible.
-
6' 3"
-
5' 10"
-
6' 0"
-
5' 11"
Now We discover Peter Bach's Biography, Age, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of net worth at the age of 58 years old?
Popular As |
N/A |
Occupation |
N/A |
Peter Bach Age |
58 years old |
Zodiac Sign |
N/A |
Born |
|
Birthday |
|
Birthplace |
N/A |
Nationality |
|
We recommend you to check the complete list of Famous People born on .
He is a member of famous Researcher with the age 58 years old group.
Peter Bach Weight & Measurements
Physical Status |
Weight |
Not Available |
Body Measurements |
Not Available |
Eye Color |
Not Available |
Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
Family |
Parents |
Not Available |
Wife |
Not Available |
Sibling |
Not Available |
Children |
Not Available |
Peter Bach Net Worth
He net worth has been growing significantly in 2021-22. So, how much is Peter Bach worth at the age of 58 years old? Peter Bach’s income source is mostly from being a successful Researcher. He is from . We have estimated
Peter Bach's net worth
, money, salary, income, and assets.
Net Worth in 2022 |
$1 Million - $5 Million |
Salary in 2022 |
Under Review |
Net Worth in 2021 |
Pending |
Salary in 2021 |
Under Review |
House |
Not Available |
Cars |
Not Available |
Source of Income |
Researcher |
Peter Bach Social Network
Timeline
Bach chronicled his wife Ruth’s treatment for early breast cancer in a series of articles for the New York Times, and then wrote about her death from the disease in a piece for New York Magazine. Bach discussed the article on Leonard Lopate's show on WNYC.
In 2015, Bach released DrugAbacus, billed as an interactive tool that users can apply to model prices for cancer drugs based on a number of factors, including clinical efficacy, safety and toxicity, the value placed on a year of life, and the value of innovation. The tool then allows users to compare the generated values with existing drug prices. Additionally, Bach co-authored a paper published in the American Medical Association in which he described possible value-based drug pricing approaches in the United States.
In 2012, Bach, who is a frequent critic of pharmaceutical pricing in cancer, co-authored an opinion piece in the New York Times outlining Memorial Sloan Kettering’s decision not to offer a new cancer drug, Zaltrap, to its patients due to the drug's price. At the time, the price for Zaltrap was more than twice as high than another cancer drug already being used by the hospital to treat colorectal cancer with similar efficacy. The New York Times piece by Bach was discussed in a 60 Minutes segment highlighting the rising cost of cancer drugs. Bach was seen as influential in the eventual lowering of Zaltrap's price by the manufacturer Sanofi.
Bach has also worked on areas related to racial disparities within the provision of cancer care. Along with research collaborators, he has published evidence that black Medicare beneficiaries with lung cancer do not receive as high quality care as white patients. A paper in 2007 demonstrated that care in Medicare is highly fragmented, with the average beneficiary seeing multiple primary care physicians and specialists. He has worked on developing lung cancer screening guidelines also developed a lung cancer risk prediction model. He has proposed a number of strategies by which Medicare could link payment level to the value of healthcare delivered.
Bach earned a bachelor's degree in English and American Literature from Harvard University (1986), a MD from the University of Minnesota (1992) and a Masters of Arts in Public Policy (1997) from the University of Chicago. He obtained his internal medicine training at Johns Hopkins Hospital, and completed a fellowship in Pulmonary and Critical Care Medicine at the University of Chicago and Johns Hopkins Hospital.